Dydrogesterone

Generic Name: Dydrogesterone

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₈O_₂

CAS Number: 152-62-5

Unique Ingredient Identifier: 90I02KLE8K

Background: A synthetic progestational hormone with no androgenic or estrogenic properties. Unlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit ovulation.

Indication: Used to treat irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency. Also used to prevent natural abortion in patients who have a history of habitual abortions.

Associated Conditions: Infertility, Menstrual Distress (Dysmenorrhea), Premenstrual Syndrome (PMS), Recurrent Miscarriages, Spontaneous Abortions

Associated Therapies: Assisted Reproductive Technology therapy, Menstrual Regulation

Clinical Trials

Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes

Phase 3

Recruiting

Conditions: IVF

Interventions: Drug: Dydrogesterone
Drug: Cetrorelix acetate
Drug: Triptorelin

First Posted Date: 2023-08-02

Last Posted Date: 2023-08-02

Lead Sponsor: Beni-Suef University

Target Recruit Count: 387

Registration Number: NCT05972902

Locations: 🇪🇬
Beni-suef university Hospital, Banī Suwayf, Beni Suef, Egypt

Comparison of 3 Different Protocols for Preventing Premature Ovulation in Ovarian Stimulation Cycles

Not Applicable

Completed

Conditions: Infertility

Interventions: Drug: Gonadotropin releasing hormone antagonist (Cetrotide)
Drug: Medroxyprogesterone Acetate (Tarlusal)
Drug: Dydrogesterone

First Posted Date: 2023-03-14

Last Posted Date: 2024-10-11

Lead Sponsor: Bezmialem Vakif University

Target Recruit Count: 297

Registration Number: NCT05767086

Locations: 🇹🇷
Bezmialem Vakif University, Istanbul, Turkey

The Rescue of Hormonal Replacement Frozen Embryo Transfer Cycle With Low Serum Progesterone.

Phase 2

Recruiting

Conditions: Hormonal Replacement Frozen Embryo Transfer Cycle

Interventions: Drug: prolutex
Drug: Duphaston

First Posted Date: 2023-03-07

Last Posted Date: 2023-03-07

Lead Sponsor: El Shatby University Hospital for Obstetrics and Gynecology

Target Recruit Count: 120

Registration Number: NCT05758064

Locations: 🇪🇬
Elshatby University Maternity Hospital, Alexandria, Egypt
🇪🇬
Faculty of Medicine, University of Alexandria, Alexandria, Egypt

DYG Versus Cetrorelix in Oocyte Donation

Completed

Conditions: Infertility, Female
Fertility Disorders

Interventions: Drug: Dydrogesterone

First Posted Date: 2022-10-13

Last Posted Date: 2022-10-13

Lead Sponsor: Clinica de la Mujer Medicina Reproductiva, Chile

Target Recruit Count: 202

Registration Number: NCT05577806

Luteal Phase Ovarian Stimulation With Follitropin Delta and Dydrogesterone

Not Applicable

Recruiting

Conditions: Oocyte Donation
Oocyte Donors

Interventions: Drug: Follitropin delta (Rekovelle)
Drug: Duphaston
Drug: GnRH agonist (Gonapeptyl)

First Posted Date: 2022-08-30

Last Posted Date: 2024-02-08

Lead Sponsor: CRG UZ Brussel

Target Recruit Count: 50

Registration Number: NCT05521828

Locations: 🇧🇪
Brussels Ivf, Brüssel, Belgium

Comparative Study to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Estradiol / Dydrogesterone in Perimenopausal Women

Phase 4

Conditions: Perimenopausal Disorder
Hot Flashes

Interventions: Drug: Femoston® 1, Femoston® 2
Drug: Klimadynon
Drug: Duphaston
Drug: Divigel

First Posted Date: 2021-12-14

Last Posted Date: 2022-01-06

Lead Sponsor: Scientific Research Institute of Public Health, Russian Federation

Target Recruit Count: 150

Registration Number: NCT05156814

Locations: 🇷🇺
Federal State Budget Institution "National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov", Moscow, Russian Federation

Oral Progesterone for Prevention of Miscarriage in Threatened Abortion

Phase 4

Completed

Conditions: Threatened Abortion

Interventions: Drug: Placebo
Drug: Dydrogesterone

First Posted Date: 2021-03-09

Last Posted Date: 2023-08-30

Lead Sponsor: Chulalongkorn University

Target Recruit Count: 100

Registration Number: NCT04788108

Locations: 🇹🇭
Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders

Phase 3

Completed

Conditions: Infertility, Female

Interventions: Drug: Duphaston
Drug: Cetrotide Injectable Product
Drug: Gonadotropin
Drug: Decapeptyl
Drug: Combined Oral Contraceptive
Drug: Chorionic Gonadotropin
Drug: Cyclo-Progynova
Drug: progesterone

First Posted Date: 2020-09-03

Last Posted Date: 2022-02-17

Lead Sponsor: El Shatby University Hospital for Obstetrics and Gynecology

Target Recruit Count: 90

Registration Number: NCT04537078

Locations: 🇪🇬
Elshatby University Maternity Hospital, Alexandria, Egypt

The Effect of Dydrogesterone on Sexual Function in Women With Endometriosis

Not Applicable

Completed

Conditions: Sexual Dysfunction
Endometriosis

Interventions: Drug: Dydrogesterone

First Posted Date: 2020-02-27

Last Posted Date: 2020-03-18

Lead Sponsor: Kanuni Sultan Suleyman Training and Research Hospital

Target Recruit Count: 79

Registration Number: NCT04287205

Locations: 🇹🇷
Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey

Oral Dydrogesterone in the Management of Preterm Labor

Phase 4

Completed

Conditions: Preterm Labor

Interventions: Drug: placebo
Drug: Dydrogesterone

First Posted Date: 2019-05-02

Last Posted Date: 2021-01-22

Lead Sponsor: Chulalongkorn University

Target Recruit Count: 48

Registration Number: NCT03935152

Locations: 🇹🇭
Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy